We remain very optimistic for the oncology market and its players after attending the ASCO (American Society of Clinical Oncology) 2015 in Chicago, the world’s most important oncology congress.
Its annual meeting is the biggest and most important oncology conference throughout the year. More than 30000 attendees got updates on clinical trials, evolving science and just about everything else around oncology. Immunooncology (IO) was the key theme at the conference with very promising developments. However, new therapies are also needed for patients not responding to IO treatments.
Did you know that R&D expenses of the 15 biggest pharma companies have increased by almost 50% since 2016 to USD 133 bn in 2021? And expenses will continue to increase. Roche alone for example will spend close to CHF 15 bn on R&D in 2022, 1 bn more than in 2021.
We attended the ESMO (European Society for Medical Oncology) annual oncology congress in Paris from Sept. 9-13. We came away very positive from the meeting, though two souls remain in our chest. On one side we see the amazing potential and the opportunities for new oncology therapies. On the other side complexity seems to potentially increase and so does competition in the space. But what to do as an investor? Find some proposals in our ESMO Thoughts from the Street.
September is traditionally one of the most important conference months, as second quarter reporting is largely complete and third quarter reporting has not yet started. We attended the 19th annual Goldman Sachs European Medtech and HC Services Conference 2022, held in London on September 7-8, again in a physical setting. While we remain mindful of all the sector headwinds, we left the conference more convinced that there are selectively attractive investment opportunities at current levels.